Causal effects of antihypertensive drugs on thyroid diseases: A trans-ancestry drug-target Mendelian randomization study.
6 affiliations
- 1Department of Endocrinology and Metabolism, Affiliated Hospital of Southwest Medical University, Luzhou, China.
- 2Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, China.
- 3Sichuan Clinical Research Center for Diabetes and Metabolism, Luzhou, China.
- 4Sichuan Clinical Research Center for Nephropathy, Luzhou, China.
- 5Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, China.
- 6Department of Endocrinology and Metabolism, Wenjiang District People's Hospital, Chengdu, China.
Abstract
Thyroid disorders frequently coexist with cardiovascular disease, including hypertension, but whether long-term modulation of antihypertensive drug targets influences thyroid disease risk remains uncertain. We aimed to evaluate the associations of 7 antihypertensive drug-target classes with thyroid diseases in European and East Asian populations using a trans-ancestry drug-target Mendelian randomization (MR) framework. We performed a two-sample, trans-ancestry drug-target MR analysis of 7 antihypertensive target classes. Target-proximal single-nucleotide polymorphisms associated with systolic blood pressure (SBP) were used as genetic proxies. Estimates were scaled per 1-mm Hg genetically predicted increase in SBP; the putative effect of target inhibition that lowers SBP was therefore interpreted in the opposite direction. Summary statistics were obtained for 4 primary thyroid diseases, benign thyroid tumors where available, and 3 thyroid-related proteins in European and East Asian datasets. Hypertension was used as a positive-control outcome. Random-effects inverse-variance weighting was the primary method, with Wald ratio estimation for single-nucleotide polymorphism instruments and weighted-median, Cochran's Q, MR-Egger, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier analyses as sensitivity assessments. Within the European populace, genetic surrogates for β-blockers exhibit (odds ratio = 0.93; 95% confidence interval = 0.87-0.99) a close association with heightened susceptibility to thyroid carcinoma, whereas KCNH2 (1.15; 1.01-1.32) demonstrates an inverse correlation with thyroid cancer risk. Moreover, calcium channel blockers exhibit a conspicuous linkage with an elevated incidence of hyperthyroidism (0.97; 0.96-0.99) alongside a diminished likelihood of thyroid cancer (1.07; 1.03-1.10). CYP17A1 exerts a protective influence against hyperthyroidism (1.04; 10.1-1.07) and Graves disease (1.10; 1.05-1.16) but manifests a pathogenic effect concerning hypothyroidism (0.99; 0.97-1.00) and thyroid cancer (0.92; 0.86-0.98). Conversely, KCNJ11 demonstrates a proximate correlation between diminished hypothyroidism risk and augmented thyroid cancer susceptibility (0.83; 0.73-0.95). Analogous estimations were noted for CYP17A1 within the East Asian cohort. Genetically proxied perturbation of several antihypertensive drug targets was associated with thyroid disease risk, with CYP17A1 showing the broadest cross-ancestry pattern. These estimates reflect lifelong target-proximal genetic effects rather than the clinical effects of prescribed drugs and should be considered hypothesis-generating pending replication, pharmacoepidemiological studies, and randomized clinical trials.
Related
- Antihypertensive drug targets and pancreatitis reporting signals: An integrative mendelian randomization and FAERS pharmacovigilance study
- Genetic Liability to Psychiatric Disorder and Risk of Musculoskeletal Diseases: A Bidirectional Mendelian Randomization Study
- Mendelian Randomization-Based Analysis of Causal Effects Between Statins and Common Upper Gastrointestinal Diseases.
- Associations of Blood Lipid Traits with Cognitive-Related Outcomes and Their Sensitivity to APOE-Region Instrumental Variables: A Mendelian Randomization and Colocalization Study
- The relationship between genetic bone mineral density and spinal stenosis: a Mendelian randomization and cohort study
BibTeX
@article{wang2026causal,
title = {{Causal effects of antihypertensive drugs on thyroid diseases: A trans-ancestry drug-target Mendelian randomization study.}},
author = {Xiao-Hong Wang and Yue-Yang Zhang and Qin Wan},
journal = {Medicine},
year = {2026},
month = oct,
doi = {10.1097/md.0000000000051090},
url = {https://europepmc.org/article/MED/42888544},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Causal effects of antihypertensive drugs on thyroid diseases: A trans-ancestry drug-target Mendelian randomization study.
AU - Xiao-Hong Wang
AU - Yue-Yang Zhang
AU - Qin Wan
PY - 2026
DA - 2026/10/01
JO - Medicine
DO - 10.1097/md.0000000000051090
UR - https://europepmc.org/article/MED/42888544
AB - Thyroid disorders frequently coexist with cardiovascular disease, including hypertension, but whether long-term modulation of antihypertensive drug targets influences thyroid disease risk remains uncertain. We aimed to evaluate the associations of 7 antihypertensive drug-target classes with thyroid diseases in European and East Asian populations using a trans-ancestry drug-target Mendelian randomization (MR) framework. We performed a two-sample, trans-ancestry drug-target MR analysis of 7 antihypertensive target classes. Target-proximal single-nucleotide polymorphisms associated with systolic blood pressure (SBP) were used as genetic proxies. Estimates were scaled per 1-mm Hg genetically predicted increase in SBP; the putative effect of target inhibition that lowers SBP was therefore interpreted in the opposite direction. Summary statistics were obtained for 4 primary thyroid diseases, benign thyroid tumors where available, and 3 thyroid-related proteins in European and East Asian datasets. Hypertension was used as a positive-control outcome. Random-effects inverse-variance weighting was the primary method, with Wald ratio estimation for single-nucleotide polymorphism instruments and weighted-median, Cochran's Q, MR-Egger, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier analyses as sensitivity assessments. Within the European populace, genetic surrogates for β-blockers exhibit (odds ratio = 0.93; 95% confidence interval = 0.87-0.99) a close association with heightened susceptibility to thyroid carcinoma, whereas KCNH2 (1.15; 1.01-1.32) demonstrates an inverse correlation with thyroid cancer risk. Moreover, calcium channel blockers exhibit a conspicuous linkage with an elevated incidence of hyperthyroidism (0.97; 0.96-0.99) alongside a diminished likelihood of thyroid cancer (1.07; 1.03-1.10). CYP17A1 exerts a protective influence against hyperthyroidism (1.04; 10.1-1.07) and Graves disease (1.10; 1.05-1.16) but manifests a pathogenic effect concerning hypothyroidism (0.99; 0.97-1.00) and thyroid cancer (0.92; 0.86-0.98). Conversely, KCNJ11 demonstrates a proximate correlation between diminished hypothyroidism risk and augmented thyroid cancer susceptibility (0.83; 0.73-0.95). Analogous estimations were noted for CYP17A1 within the East Asian cohort. Genetically proxied perturbation of several antihypertensive drug targets was associated with thyroid disease risk, with CYP17A1 showing the broadest cross-ancestry pattern. These estimates reflect lifelong target-proximal genetic effects rather than the clinical effects of prescribed drugs and should be considered hypothesis-generating pending replication, pharmacoepidemiological studies, and randomized clinical trials.
SN - 0304-5412
SN - 1536-5964
ER -